Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581234 | 0.96 | ALDH1A1 (0.39) | P2RX7RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2587657 | 0.96 | ALDH1A1 (0.39) | P2RX7RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL4521177 | 0.94 | P2RX7 (0.39) | P2RX7RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL4521180 | 0.94 | P2RX7 (0.39) | P2RX7RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2583972 | 0.94 | P2RX7 (0.39) | P2RX7RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2581567 | 0.89 | P2RX7 (0.41) | P2RX7RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2577904 | 0.85 | P2RX7 (0.33) | P2RX7MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL4513877 | 0.85 | L3MBTL1 (0.34) | P2RX7RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2586430 | 0.84 | RIPK1 (0.34) | P2RX7RIPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2581032 | 0.82 | RIPK1 (0.48) | P2RX7RIPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203697-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | CLIC4, NR3C2, MAN2B1 | P2RX7 2211/4885RIPK1 4835/4885MEN1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.